CARDIOME PHARMA CORP's ticker is CRME and the CUSIP is 14159U301. A total of 26 filers reported holding CARDIOME PHARMA CORP in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $2,784,000 | +49.7% | 1,200,000 | 0.0% | 0.12% | +41.7% |
| Q4 2017 | $1,860,000 | -27.6% | 1,200,000 | 0.0% | 0.08% | -28.8% |
| Q3 2017 | $2,568,000 | -52.7% | 1,200,000 | 0.0% | 0.12% | -56.9% |
| Q2 2017 | $5,424,000 | +50.2% | 1,200,000 | 0.0% | 0.27% | +31.7% |
| Q1 2017 | $3,612,000 | +9.1% | 1,200,000 | 0.0% | 0.21% | -6.3% |
| Q4 2016 | $3,312,000 | -11.7% | 1,200,000 | 0.0% | 0.22% | -5.5% |
| Q3 2016 | $3,751,000 | -38.9% | 1,200,000 | 0.0% | 0.24% | -48.4% |
| Q2 2016 | $6,144,000 | +26.2% | 1,200,000 | +0.8% | 0.46% | +11.5% |
| Q1 2016 | $4,867,000 | -49.6% | 1,190,000 | 0.0% | 0.41% | -44.2% |
| Q4 2015 | $9,651,000 | -3.9% | 1,190,000 | 0.0% | 0.73% | -10.3% |
| Q3 2015 | $10,044,000 | +70.8% | 1,190,000 | +90.4% | 0.82% | +90.0% |
| Q2 2015 | $5,881,000 | +12.4% | 625,000 | +10.6% | 0.43% | -12.3% |
| Q1 2015 | $5,232,000 | – | 565,000 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 1,918,722 | $6,006,000 | 4.90% |
| Tamarack Advisers, LP | 4,400,000 | $13,882,000 | 2.18% |
| AlphaOne Investment Services, LLC | 580,965 | $1,824,000 | 0.60% |
| CLOUGH CAPITAL PARTNERS L P | 3,061,064 | $9,581,000 | 0.50% |
| Rock Springs Capital Management LP | 1,200,000 | $3,751,000 | 0.24% |
| TURNER INVESTMENTS LLC | 150,000 | $470,000 | 0.16% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 5,397,007 | $16,893,000 | 0.14% |
| SABBY MANAGEMENT, LLC | 484,505 | $1,521,000 | 0.06% |
| PUTNAM INVESTMENTS LLC | 3,673,622 | $11,536,000 | 0.03% |
| ARDSLEY ADVISORY PARTNERS LP | 28,900 | $90,000 | 0.01% |